Lexicon Pharmaceuticals, Inc. (LXRX) News

Lexicon Pharmaceuticals, Inc. (LXRX): $2.19

0.21 (+10.61%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add LXRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#341 of 363

in industry

Filter LXRX News Items

LXRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LXRX News Highlights

  • For LXRX, its 30 day story count is now at 3.
  • Over the past 13 days, the trend for LXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG and DEC are the most mentioned tickers in articles about LXRX.

Latest LXRX News From Around the Web

Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Yahoo | December 26, 2023

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th. Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, an

Yahoo | December 21, 2023

MSCLF: AAK1 Disclosed as Drug Target for DMD Program…

By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update AAK1 Disclosed as Drug Target for DMD Program On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced that AAK1 is the drug target for the company’s Duchenne muscular dystrophy (DMD) program, that SAT-3247 has been nominated as the lead drug candidate, and that IND-enabling studies and GMP

Yahoo | December 13, 2023

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRE

Yahoo | November 30, 2023

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Cr

Yahoo | November 22, 2023

Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

Recent insider trading activity has caught the attention of market analysts and investors alike, as Director Philippe Amouyal has made a significant purchase of shares in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX).

Yahoo | November 15, 2023

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today

Yahoo | November 12, 2023

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on Wednesday, November 15th. A simultaneous webcast of the presentation will be ava

Yahoo | November 10, 2023

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript November 8, 2023 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. Operator: Good day and welcome to the Lexicon Pharmaceuticals’ Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, […]

Yahoo | November 10, 2023

Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call

Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call

Yahoo | November 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!